Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Depreciation and Depletion (2023 - 2025)

Historic Depreciation and Depletion for Standard Biotools (LAB) over the last 3 years, with Q3 2025 value amounting to $1.5 million.

  • Standard Biotools' Depreciation and Depletion rose 5000.0% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.8 million, marking a year-over-year increase of 3684.21%. This contributed to the annual value of $3.4 million for FY2023, which is 2142.86% up from last year.
  • Per Standard Biotools' latest filing, its Depreciation and Depletion stood at $1.5 million for Q3 2025, which was up 5000.0% from $2.0 million recorded in Q2 2025.
  • Over the past 5 years, Standard Biotools' Depreciation and Depletion peaked at $3.3 million during Q1 2025, and registered a low of $700000.0 during Q1 2023.
  • Over the past 3 years, Standard Biotools' median Depreciation and Depletion value was $1.5 million (recorded in 2025), while the average stood at $1.8 million.
  • As far as peak fluctuations go, Standard Biotools' Depreciation and Depletion skyrocketed by 32857.14% in 2024, and later soared by 1000.0% in 2025.
  • Quarter analysis of 3 years shows Standard Biotools' Depreciation and Depletion stood at $700000.0 in 2023, then soared by 42.86% to $1.0 million in 2024, then skyrocketed by 50.0% to $1.5 million in 2025.
  • Its Depreciation and Depletion stands at $1.5 million for Q3 2025, versus $2.0 million for Q2 2025 and $3.3 million for Q1 2025.